HC Wainwright Issues Optimistic Estimate for MLTX Earnings

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Analysts at HC Wainwright increased their Q2 2026 earnings per share (EPS) estimates for MoonLake Immunotherapeutics in a research note issued on Monday, July 20th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.75) per share for the quarter, up from their previous forecast of ($0.81). HC Wainwright currently has a “Buy” rating and a $45.00 target price on the stock. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($3.64) per share. HC Wainwright also issued estimates for MoonLake Immunotherapeutics’ Q3 2026 earnings at ($0.62) EPS, Q4 2026 earnings at ($0.59) EPS, FY2026 earnings at ($2.90) EPS, Q1 2027 earnings at ($0.57) EPS, Q2 2027 earnings at ($0.67) EPS, Q3 2027 earnings at ($0.75) EPS, Q4 2027 earnings at ($0.55) EPS and FY2027 earnings at ($2.54) EPS.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.07).

MLTX has been the subject of several other research reports. Weiss Ratings restated a “sell (e+)” rating on shares of MoonLake Immunotherapeutics in a research report on Tuesday, May 12th. Leerink Partners raised their price target on shares of MoonLake Immunotherapeutics from $24.00 to $29.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 1st. Needham & Company LLC lifted their price target on shares of MoonLake Immunotherapeutics from $25.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, May 12th. Finally, BTIG Research reissued a “buy” rating and set a $30.00 price objective on shares of MoonLake Immunotherapeutics in a report on Tuesday, June 9th. Ten research analysts have rated the stock with a Buy rating, four have issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, MoonLake Immunotherapeutics has an average rating of “Hold” and a consensus price target of $24.21.

MoonLake Immunotherapeutics Trading Down 5.6%

Shares of MoonLake Immunotherapeutics stock opened at $18.94 on Wednesday. MoonLake Immunotherapeutics has a 1 year low of $5.95 and a 1 year high of $62.75. The firm has a market cap of $1.39 billion, a PE ratio of -4.89 and a beta of 1.04. The stock has a fifty day moving average price of $18.92 and a 200-day moving average price of $17.59. The company has a debt-to-equity ratio of 0.39, a current ratio of 8.60 and a quick ratio of 8.60.

Insider Activity at MoonLake Immunotherapeutics

In other news, insider Kristian Reich sold 50,000 shares of the company’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $19.43, for a total value of $971,500.00. Following the transaction, the insider owned 2,824,551 shares of the company’s stock, valued at approximately $54,881,025.93. This represents a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Da Silva Jorge Santos sold 68,289 shares of the company’s stock in a transaction on Friday, July 10th. The stock was sold at an average price of $20.02, for a total transaction of $1,367,145.78. Following the completion of the transaction, the chief executive officer directly owned 2,774,893 shares in the company, valued at approximately $55,553,357.86. The trade was a 2.40% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 250,000 shares of company stock worth $4,919,138 over the last quarter. Corporate insiders own 10.40% of the company’s stock.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

A number of institutional investors have recently added to or reduced their stakes in MLTX. Kestra Advisory Services LLC bought a new stake in shares of MoonLake Immunotherapeutics during the 4th quarter valued at about $26,000. EverSource Wealth Advisors LLC grew its holdings in shares of MoonLake Immunotherapeutics by 221.1% during the first quarter. EverSource Wealth Advisors LLC now owns 2,867 shares of the company’s stock worth $53,000 after purchasing an additional 1,974 shares in the last quarter. FNY Investment Advisers LLC bought a new position in shares of MoonLake Immunotherapeutics in the second quarter worth approximately $58,000. Russell Investments Group Ltd. increased its position in shares of MoonLake Immunotherapeutics by 45.4% in the fourth quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company’s stock worth $45,000 after purchasing an additional 1,069 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. purchased a new stake in MoonLake Immunotherapeutics in the fourth quarter valued at approximately $47,000. 93.85% of the stock is currently owned by institutional investors.

MoonLake Immunotherapeutics News Roundup

Here are the key news stories impacting MoonLake Immunotherapeutics this week:

• Neutral Sentiment: HC Wainwright reaffirmed a bullish stance on MoonLake Immunotherapeutics, keeping a Buy rating and $45 price target in place. HC Wainwright Reaffirms Buy Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX)
• Positive Sentiment: Analysts improved near-term earnings estimates for Q2 2026, Q3 2026, Q4 2026, and Q1 2027, suggesting slightly better expected operating performance in the next several quarters.
• Positive Sentiment: FY2026 and FY2027 loss forecasts were also reduced, which may be interpreted as a modest improvement in the company’s longer-term earnings path.
• Negative Sentiment: Q3 2027 earnings estimates were cut, and the stock may be under pressure because investors are focusing on the mixed nature of the revisions rather than the Buy rating.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.